Our research focuses on prevention of colonic inflammation (inflammatory bowel disease) and colon cancer. To achieve this, we address two major issues: (1) identification of novel risk factors of IBD and colon cancer. We study how environmental and dietary compounds alter gut microbiome and deregulate mucosa immune system to exaggerate colonic inflammation and colon tumorigenesis; and (2) discovery of novel therapeutic targets and biomarkers of IBD and colon cancer. We use LC-MS/MS-based lipidomics and transgenic animal models to study the roles of eicosanoid signaling in colonic inflammation and colon cancer, in order to identify novel therapeutic targets and biomarkers of these diseases.

